December 22nd, 2011 by GruntDoc in News
No Comments »
Aah, the French:
The idea of putting maggots into open flesh may sound repulsive, but such a therapy might be a quick way to clean wounds, a new study from France suggests.
via Maggots Clean Wounds Faster Than Surgeons | Wound Healing | LiveScience.
I kid. I think this is a good idea, and it’s natures’ way of saying ‘cleanup on aisle three’. Patients not infrequently will be brought to the ED with awful, non-healing wounds infested with maggots.
We typically kill them off, more because a) the staff is completely grossed out and b) if you’re living at home and have maggots in your wounds, let’s just say your personal hygiene is deeply suspect. Rank, in fact. Needs a decon level bad.
However, there is a legitimate role for biological wound cleaning; I have a WWII surgical book with a chapter in it on growing your own sterile maggots. It’s not an ER thing, but it’s yet another tool in the armamentarium of bad wounds.
*This blog post was originally published at GruntDoc*
December 18th, 2011 by Berci in Better Health Network
No Comments »
I remember when I had to study all the details of human anatomy from textbooks and some old books with many pictures, but I didn’t have a chance to see things in 3D (which would have made it much easier to understand, learn and memorize). After medical school, I started to discover new apps and solutions for this problem.
I’ve been using the Biodigital app on Google Chrome, it’s free but a bit hard to use.
And recently, Read more »
*This blog post was originally published at ScienceRoll*
December 16th, 2011 by GruntDoc in Opinion, Research
No Comments »
I read this headline and said, “Wow!, finally I won’t need to CT all those patients’ heads!”
FDA permits marketing of the first hand-held device to aid in the detection of bleeding in the skull
Helps to determine if immediate CT scan is needed
The U.S. Food and Drug Administration today allowed marketing of the first hand-held device intended to aid in the detection of life-threatening bleeding in the skull called intracranial hematomas, using near-infrared spectroscopy.
via Press Announcements > FDA permits marketing of the first hand-held device to aid in the detection of bleeding in the skull.
But then, wait, said I, is it any good? Read more »
*This blog post was originally published at GruntDoc*
December 7th, 2011 by Berci in Medical Art
No Comments »
It’s quite clear not everyone would like to read long medical reports and text as sometimes a well-designed and structured graph can say more than a hundred words. Do you remember the Wired article about the blood test makeover that described how our blood test results would be designed to show more easily understandable information to patients?
Well, this Venn diagram shows many things about hemorrhoids and related symptoms. And it’s not even a new infographics published on a blog but is from an old textbook which means the concept has been there for a long time but it always disappears in medicine.
*This blog post was originally published at ScienceRoll*
December 6th, 2011 by DrWes in Opinion
3 Comments »
Several days ago, the world’s leading cholesterol-lowering “statin” drug, Lipitor, went generic. Doctors are bearing the brunt of the conversion with little information about what the new drug will cost for their patients.
This, of course, is the plan.
Even the Wall Street Journal which has an excellent “user’s guide” to making the switch from name-brand to generic Lipitor offers little help as it mentions “co-pays” rather than actual drug cost:
How much cheaper will generic Lipitor be?
Insurance copayments should drop considerably, if patients are getting Lipitor or atorvastatin on the generic tier of their health plans. Currently, Lipitor has been on a higher, branded tier for prescription drugs. Copays for branded drugs average either $29 or $49 depending on the tier, according to Kaiser Family Foundation. Copays for generics average $10.
In addition, Ranbaxy Laboratories Ltd, one of the generic manufacturers of generic Lipitor, won concessions to maintain elevated prices for 180 days from the government (a la our own Food and Drug Administration while the Federal Trade Commission stands idly by complaining how consumers are gouged with this arrangement) to assure prices stay high a bit longer.
But if we forget the insurers and copays, how much will the generic drug actually cost consumers? Read more »
